Kirby McInerney LLP is investigating potential claims against the Board of Directors of Chindex International, Inc. (“Chindex” or the “Company”) (NASDAQ:CHDX) concerning the proposed acquisition of the Company by a consortium led by an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Roberta Lipson, the CEO of Chindex. Under the terms of the definitive merger agreement, Chindex stockholders will receive $19.50 in cash for each share of Chindex owned, representing an implied equity value of approximately $369 million.

The investigation concerns whether the Chindex Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values Chindex’s common stock.

If you are a Chindex stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Copyright Business Wire 2010